Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation.

Sasaki H, Mitani S, Kusumoto S, Marumo Y, Asano A, Yoshida T, Narita T, Ito A, Yano H, Ri M, Ishida T, Komatsu H, Iida S.

Int J Hematol. 2019 Mar 16. doi: 10.1007/s12185-019-02628-8. [Epub ahead of print]

PMID:
30879266
2.

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.

Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE.

Cancer. 2017 Aug 1;123(15):2875-2880. doi: 10.1002/cncr.30558. Epub 2017 Apr 7.

3.

Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.

Xu LP, Xu ZL, Zhang XH, Chen H, Chen YH, Han W, Chen Y, Wang FR, Wang JZ, Wang Y, Yan CH, Mo XD, Liu KY, Huang XJ.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1080-1086. doi: 10.1016/j.bbmt.2016.03.012. Epub 2016 Mar 16.

4.

Hematopoietic stem cell transplantation for T315I-mutated chronic myelogenous leukemia.

Basak G, Torosian T, Snarski E, Niesiobedzka J, Majewski M, Gronkowska A, Urbanowska E, Jedrzejczak W.

Ann Transplant. 2010 Apr-Jun;15(2):68-70.

PMID:
20657522
5.

Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.

Petrungaro A, Gentile M, Mazzone C, Greco R, Uccello G, Recchia AG, De Stefano L, Bossio S, Palummo A, Morelli R, Musolino C, Morabito F, Vigna E.

Chemotherapy. 2017;62(6):353-356. doi: 10.1159/000477714. Epub 2017 Aug 16.

6.

Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant.

Renzi D, Marchesi F, De Angelis G, Elia L, Salvatorelli E, Gumenyuk S, Palombi F, Pisani F, Romano A, Spadea A, Papa E, Canfora M, Arcese W, Mengarelli A; Rome Transplant Network.

Chemotherapy. 2017;62(1):58-61. Epub 2016 Sep 10.

7.

Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case.

Bucelli C, Cattaneo D, Ferla V, Zappa M, de Benedittis C, Soverini S, Iurlo A.

Case Rep Hematol. 2017;2017:6167345. doi: 10.1155/2017/6167345. Epub 2017 Aug 14.

8.
9.

[Allo-geneic hematopoietic stem cell transplantation in treatment with T315I mutation of chronic myelogenous leukemia].

Wang L, Liu H, Zheng C, Tang B, Zhu X, Yao W, Zhang L, Sun Z.

Zhonghua Yi Xue Za Zhi. 2014 Nov 4;94(40):3150-3. Chinese.

PMID:
25573310
10.

Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia.

Tachibana T, Koyama S, Andou T, Ishiyama Y, Tanaka M, Nakajima H, Kanamori H.

Int J Hematol. 2019 Feb;109(2):162-168. doi: 10.1007/s12185-018-02571-0. Epub 2018 Dec 3.

PMID:
30511314
11.

Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Shamroe CL, Comeau JM.

Ann Pharmacother. 2013 Nov;47(11):1540-6. doi: 10.1177/1060028013501144. Epub 2013 Nov 21. Review.

PMID:
24265264
12.

Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.

Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H.

Cytotherapy. 2001;3(4):253-60.

PMID:
12171713
13.

[Chronic myeloid leukemia harboring T315I and F317L mutations successfully treated with interferon-α and ponatinib].

Motomura Y, Arai K, Yoshifuji K, Sonokawa S, Suzuki S, Kumagai T.

Rinsho Ketsueki. 2019;60(1):33-38. doi: 10.11406/rinketsu.60.33. Japanese.

PMID:
30726822
14.

Extramedullary Blast Crisis in a Patient with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.

Zhang J, Zhang X, Lu Y, Jiao J, Chen Y, Lin D.

Clin Lab. 2018 Jan 1;64(1):193-196. doi: 10.7754/Clin.Lab.2017.170807.

PMID:
29479884
15.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators.

N Engl J Med. 2013 Nov 7;369(19):1783-96. doi: 10.1056/NEJMoa1306494. Epub 2013 Nov 1.

16.

Chronic myeloid leukemia relapsing ten years after allogenic bone marrow transplantation.

Hino Y, Doki N, Yamamoto K, Senoo Y, Sasajima S, Sakaguchi M, Hattori K, Kaito S, Kurosawa S, Harada K, Ikegawa S, Watanabe D, Hagino T, Yoshioka K, Watakabe K, Igarashi A, Najima Y, Kobayashi T, Kakihana K, Sakamaki H, Ohashi K.

Rinsho Ketsueki. 2016 May;57(5):608-12. doi: 10.11406/rinketsu.57.608. Japanese.

PMID:
27263786
17.

Targeted chronic myeloid leukemia therapy: seeking a cure.

Fausel C.

J Manag Care Pharm. 2007 Oct;13(8 Suppl A):8-12. Review.

18.

Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia.

Price KE, Saleem N, Lee G, Steinberg M.

Onco Targets Ther. 2013 Aug 20;6:1111-8. doi: 10.2147/OTT.S36980. eCollection 2013.

19.

[Sudden blast crisis of chronic myeloid leukemia after a 13-year durable remission following allogeneic bone marrow transplantation and donor lymphocyte infusion].

Ookura M, Yamauchi T, Negoro E, Hosono N, Kishi S, Inai K, Wano Y, Matsumoto K, Iwasaki H, Morita K, Ueda T.

Gan To Kagaku Ryoho. 2014 Feb;41(2):265-8. Japanese.

PMID:
24743212
20.

Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation.

Ferri CA, Bianchini M, Bengió RM, Moiraghi EB, Gonzalez MS, Noriega MF, Larripa IB.

Eur J Haematol. 2015 Mar;94(3):270-2. doi: 10.1111/ejh.12358. Epub 2014 May 13.

PMID:
24766374

Supplemental Content

Support Center